Loading asset research
CAMP4 Therapeutics Corporation Common Stock
CAMPNasdaq · USD · StocksQuote as of · Exchange session not verified$4.27
-1.61%
Today
CAMP
Loading 1D prices…
Market cap
$266.7M
Volume
101.1K
52w high
$7.7552w low
$2.20Company profile
CAMP4 Therapeutics Corporation Common Stock
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Cambridge, MA, United States
Employees
48
Fiscal year end
1231
CIK
1736730
Session & valuation
Open$4.46
Previous close$4.34
Day high$4.54
Day low$4.21
30-day avg. volume272.5K
Outstanding shares62.8M
Diluted EPS-$2.65
Latest annual period
P/E (trailing)-1.61
P/E (forward)-5.35
Price / book-326.92
Beta—
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| PYXSPyxis Oncology Inc. Common Stock | $267.7M | $13.9M | -574.55% | -$1.28 | -1.83% | Buy |
| ALXOALX Oncology Holdings Inc. Common Stock | $268.3M | $0.00 | — | -$1.90 | +2.11% | Buy |
| TRDAEntrada Therapeutics Inc. Common Stock | $264.8M | $25.4M | -565.48% | -$3.47 | +6.07% | Buy |
| AKBAAkebia Therapeutics Inc. Common Stock | $263.7M | $236.2M | -2.24% | -$0.02 | +0.84% | Buy |
| BCYCBicycle Therapeutics plc American Depositary Shares | $270.2M | $72.6M | -301.66% | -$3.16 | +1.31% | Buy |